R. Le Moigne

发表

A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer

R. B. Montgomery, U. Vaishampayan, K. Chi, 2021, Investigational New Drugs.

SAR156497, an exquisitely selective inhibitor of aurora kinases.

Sébastien Maignan, François Clerc, Thomas Bertrand, 2014, Journal of medicinal chemistry.

Advances in the development of a targeted N-Terminal Domain androgen receptor (AR) degrader (ANITAC) for the treatment of prostate cancer

R. Le Moigne, N. Hong, B. Biannic, 2022, European Journal of Cancer.

Valosin-Containing Protein/p97 as a Novel Therapeutic Target in Acute Lymphoblastic Leukemia

M. Rolfe, S. Gery, Haibo Sun, 2017, Neoplasia.

Cytopathic effects of the cytomegalovirus-encoded apoptosis inhibitory protein vMIA

G. Kroemer, P. Rustin, H. Schägger, 2006, The Journal of cell biology.

Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor

S. Carr, K. Lage, K. Stegmaier, 2021, Science Translational Medicine.

The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma

Stephen T. C. Wong, P. L. Bergsagel, C. Mitsiades, 2017, Molecular Cancer Therapeutics.

Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083).

Daniel J. Anderson, M. Rolfe, F. Yakes, 2015, Journal of medicinal chemistry.

Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis.

J. Weissman, Daniel J. Anderson, M. Rolfe, 2015, Cancer cell.

CB-6644 Is a Selective Inhibitor of the RUVBL1/2 Complex with Anticancer Activity.

Yangzhong Tang, Daniel J. Anderson, M. Rolfe, 2019, ACS chemical biology.

Preclinical and clinical pharmacology of EPI-7386, an androgen receptor N-terminal domain inhibitor for castration-resistant prostate cancer.

P. David Pearson, A. Cesano, V. Lauriault, 2021, Journal of Clinical Oncology.

Phase 1/2 study of EPI-7386 in combination with enzalutamide (enz) compared with enz alone in subjects with metastatic castration-resistant prostate cancer (mCRPC).

C. Kyriakopoulos, G. Chatta, A. Cesano, 2023, Journal of Clinical Oncology.

Cytopathic effects of the cytomegalovirus-encoded apoptosis inhibitory protein vMIA

G. Kroemer, P. Rustin, H. Schägger, 2006, The Journal of cell biology.